Toxic and chemopreventive ligands preferentially activate distinct aryl hydrocarbon receptor pathways: Implications for cancer prevention

Cancer Prevention Research

Volumn 2, Issue 3, 2009, Pages 251-256

  Okino, Steven T ^a   Pookot, Deepa ^a   Basak, Shashwati ^a   Dahiya, Rajvir ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3,3' DIINDOLYLMETHANE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; ESTROGEN RECEPTOR ALPHA; SMALL INTERFERING RNA;

ARTICLE; BREAST CARCINOMA; CANCER PREVENTION; CELL STRAIN MCF 7; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; KNOCKOUT GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CARCINOGENS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; PROTEIN BINDING; RECEPTORS, ARYL HYDROCARBON; RISK; RNA, MESSENGER; RNA, SMALL INTERFERING; TETRACHLORODIBENZODIOXIN;

EID: 68349093856     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0146     Document Type: Article

References (41)

1. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-282
2. Singh RR, Kumar R. Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem 2005;96:490-505. (Pubitemid 41504648)
3. Jefcoate CR, Liehr JG, Santen RJ, et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 2000;95-112.
4. Wormke M, Stoner M, Saville B, et al. The aryl hydrocarbon receptor mediates degradation of estrogen receptor α through activation of proteasomes. Mol Cell Biol 2003;23:1843-1855 (Pubitemid 36278799)
5. Ohtake F, Baba A, Takada I, et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007;446:562-566 (Pubitemid 46514731)
6. Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 2007;55:224-236 (Pubitemid 46518152)
7. Bradlow HL, Michnovicz JJ, Halper M, Miller DG, Wong GY, Osborne MP. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol Biomarkers Prev 1994;3:591-595 (Pubitemid 24314448)
8. Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst 1997;89:718-723 (Pubitemid 27229860)
9. Wattenberg LW, Loub WD. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 1978;38:1410-1413 (Pubitemid 8323347)
10. Chen I, McDougal A, Wang F, Safe S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998;19:1631-1639 (Pubitemid 28441867)
11. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 1993;45:1129-1136
12. Bjeldanes LF, Kim JY, Grose KR, Bartholomew JC, Bradfield CA. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc Natl Acad Sci U S A 1991;88:9543-9547
13. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003;43:309-334
14. Poland A, Knutson JC. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol 1982;22:517-554
15. Okey AB. An aryl hydrocarbon receptor odyssey to the shores of toxicology: the Deichmann Lecture, International Congress of Toxicology-XI. Toxicol Sci 2007;98:5-38.
16. Okino ST, Quattrochi LC, Pookot D, Iwahashi M, Dahiya R. A dioxin-responsive enhancer 3′ of the human CYP1A2 gene. Mol Pharmacol 2007;72:1457-1465 (Pubitemid 350146083)
17. Okino ST, Pookot D, Majid S, et al. Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer. Mol Carcinog 2007;46:839-846 (Pubitemid 47549769)
18. Le HT, Schaldach CM, Firestone GL, Bjeldanes LF. Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 2003;278:21136-21145 (Pubitemid 36806427)
19. Anderton MJ, Manson MM, Verschoyle R, et al. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 2004;32:632-638 (Pubitemid 38668156)
20. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269-2277
21. Cicek M, Iwaniec UT, Goblirsch MJ, et al. 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res 2007;67:10106-10111
22. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995;35:307-340
23. Whitlock JP, Jr. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999;39:103-125
24. Hestermann EV, Brown M. Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol 2003;23:7920-7925 (Pubitemid 37271487)
25. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008;21:102-116
26. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004;279:23847-23850
27. Chen I, McDougal A, Wang F, Safe S. Aryl hydrocarbon receptor-mediated anti-estrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998;19:1631-1639 (Pubitemid 28441867)
28. McDougal A, Gupta MS, Ramamoorthy K, Sun G, Safe SH. Inhibition of carcinogen-induced rat mammary tumor growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolylmethane. Cancer Lett 2000;151:169-179 (Pubitemid 30156791)
29. McDougal A, Wilson C, Safe S. Inhibition of 7,12-dimethylbenz[a] anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett 1997;120:53-63. (Pubitemid 27483311)
30. McDougal A. Aryl hydrocarbon receptor-based antiestrogens as treatments for breast cancer [dissertation]. College Station (TX): Texas A&M University; 2000.
31. Safe S, Qin C, McDougal A. Development of selective aryl hydrocarbon receptor modulators (SARMs) for treatment of breast cancer. Expert Opin Investig Drugs 1999;8:1385-1396 (Pubitemid 29417622)
32. Kociba RJ, Keyes DG, Beyer JE, et al. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 1978;46:279-303.
33. Holcomb M, Safe S. Inhibition of 7,12-dimethyl-benzanthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett 1994;82:43-47
34. Bhuiyan MM, Li Y, Banerjee S, et al. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006;66:10064-10072 (Pubitemid 44672060)
35. Kirsh VA, Peters U, Mayne ST, et al. J Natl Cancer Inst 2007;99:1200-1209
36. Zhang S, Qin C, Safe SH. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect 2003;111:1877-1882 (Pubitemid 37541197)
37. Diel P, Olff S, Schmidt S, Michna H. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7. Planta Med 2001;67:510-514 (Pubitemid 32800414)
38. Lazarevic B, Karlsen SJ, Saatcioglu F. Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. Oncol Rep 2008;19:1231-1235
39. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552S-8S. (Pubitemid 34208769)
40. Steiner C, Amould S, Scalbert A, Manach C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 2008;99 E Suppl 1:ES78-108.
41. Safe S, Qin C, McDougal A. Development of selective aryl hydrocarbon receptor modulators for treatment of breast cancer. Expert Opin Investig Drugs 1999;8:1385-1396 (Pubitemid 29417622)